Healthcare >> CEO Interviews >> November 17, 2022
David Fischel has served as Chairman and CEO of Stereotaxis since 2017. Under his leadership, Stereotaxis has returned to financial health, reestablished commercial growth, and advanced a comprehensive innovation strategy. Prior to Stereotaxis, Mr. Fischel served as Principal and portfolio manager for medical device investments at DAFNA Capital Management, LLC. Prior to DAFNA Capital, he was a research analyst at SCP Vitalife, a health care venture capital fund. Mr. Fischel completed his B.S. magna cum laude in applied mathematics with a minor in accounting at the University of California at Los Angeles and received his MBA from Bar-Ilan University in Tel Aviv. He is a Certified Public Accountant, Chartered Financial Analyst and Chartered Alternative Investment Analyst. Profile
Word count: 3,760
TWST: You spoke with The Wall Street Transcript in 2020. I’m wondering if you could give us a recap of the history of the company up to 2020.
Mr.
